全文获取类型
收费全文 | 11377篇 |
免费 | 182篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 47篇 |
儿科学 | 1160篇 |
妇产科学 | 430篇 |
基础医学 | 1009篇 |
口腔科学 | 360篇 |
临床医学 | 445篇 |
内科学 | 2739篇 |
皮肤病学 | 370篇 |
神经病学 | 493篇 |
特种医学 | 278篇 |
外科学 | 2509篇 |
综合类 | 91篇 |
一般理论 | 1篇 |
预防医学 | 451篇 |
眼科学 | 281篇 |
药学 | 421篇 |
中国医学 | 71篇 |
肿瘤学 | 420篇 |
出版年
2023年 | 36篇 |
2022年 | 71篇 |
2021年 | 247篇 |
2020年 | 76篇 |
2019年 | 1480篇 |
2018年 | 1179篇 |
2017年 | 646篇 |
2016年 | 78篇 |
2015年 | 80篇 |
2014年 | 135篇 |
2013年 | 145篇 |
2012年 | 73篇 |
2011年 | 93篇 |
2010年 | 69篇 |
2009年 | 69篇 |
2008年 | 59篇 |
2007年 | 66篇 |
2006年 | 60篇 |
2005年 | 52篇 |
2004年 | 45篇 |
2003年 | 36篇 |
2002年 | 34篇 |
2001年 | 32篇 |
2000年 | 34篇 |
1999年 | 37篇 |
1998年 | 25篇 |
1997年 | 23篇 |
1996年 | 18篇 |
1995年 | 14篇 |
1994年 | 10篇 |
1993年 | 9篇 |
1992年 | 9篇 |
1991年 | 11篇 |
1988年 | 10篇 |
1987年 | 8篇 |
1986年 | 6篇 |
1985年 | 547篇 |
1984年 | 851篇 |
1983年 | 517篇 |
1982年 | 648篇 |
1981年 | 557篇 |
1980年 | 471篇 |
1979年 | 527篇 |
1978年 | 421篇 |
1977年 | 395篇 |
1976年 | 460篇 |
1975年 | 398篇 |
1974年 | 345篇 |
1973年 | 339篇 |
1972年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Joobin Sattar Adi Kartolo Wilma M. Hopman Joshua Matthew Lakoff Tara Baetz 《Journal of Geriatric Oncology》2019,10(3):411-414
ImportanceImmunotherapy has emerged as an effective treatment option for the management of advanced cancers. The effects of these immune checkpoint inhibitors in the older patient population has not been adequately assessed.ObjectiveTo understand the impact of aging on CTLA-4 and PDL-1 inhibitors efficacy and immune-related adverse events (irAE) in the context of real-world management of advanced solid cancers.Design, Setting, and ParticipantsThis retrospective study involved all non-study patients with histologically-confirmed metastatic or inoperable solid cancers receiving immunotherapy at Kingston Health Sciences Centre. We defined ‘older patient’ as age ≥ 75. All statistical analyses were conducted under SPSS IBM for Windows version 24.0.Main Outcomes and MeasuresStudy outcomes included immunotherapy treatment response, survival, as well as number, type, and severity of irAEs.ResultsOur study (N = 78) had 29 (37%) patients age <65, 26 (33%) patients age 65–74, and 23 (30%) patients age ≥75. Melanoma, non-small cell lung cancer, and renal cell carcinoma accounted for 70%, 22%, and 8% of the study population, respectively. Distributions of ipilimumab (32%), nivolumab (33%), and pembrolizumab (35%) were similar in the study. The response rates were 28%, 27%, and 39% in the age <65, age 64–74, age ≥75 groups, respectively (P = 0.585). Kaplan-Meier curve showed a median survival of 28 months (12.28–43.9, 95% CI) and 17 months (0–36.9, 95% CI) in the age <65 and age 64–74 groups, respectively; the estimated survival probability did not reach 50% in the age ≥75 group (P = 0.319). There were no statistically significant differences found in terms of irAEs, multiple irAEs, severity of grade 3 or higher, types of irAEs, and irAEs resolution status when comparing between different age groups.Conclusion and RelevanceOur results suggest that patients age ≥75 are able to gain as much benefit from immunotherapy as younger patients, without excess toxicity. Our findings suggest that single agent immunotherapy is generally well-tolerated across different age groups with no significant difference in the type, frequency or severity of irAEs. Future studies evaluating aging and combination immunotherapy are warranted. 相似文献
4.
《Journal of pediatric surgery》2023,58(6):1213-1218
IntroductionEndoscopic surveillance guidelines for patients with repaired esophageal atresia (EA) rely primarily on expert opinion. Prior to embarking on a prospective EA surveillance registry, we sought to understand EA surveillance practices within the Eastern Pediatric Surgery Network (EPSN).MethodsAn anonymous, 23-question Qualtrics survey was emailed to 181 physicians (surgeons and gastroenterologists) at 19 member institutions. Likert scale questions gauged agreement with international EA surveillance guideline-derived statements. Multiple-choice questions assessed individual and institutional practices.ResultsThe response rate was 77%. Most respondents (80%) strongly agree or agree that EA surveillance endoscopy should follow a set schedule, while only 36% claimed to perform routine upper GI endoscopy regardless of symptoms. Many institutions (77%) have an aerodigestive clinic, even if some lack a multi-disciplinary EA team. Most physicians (72%) expressed strong interest in helping develop evidence-based guidelines.ConclusionsOur survey reveals physician agreement with current guidelines but weak adherence. Surveillance methods vary greatly, underscoring the lack of evidence-based data to guide EA care. Aerodigestive clinics may help implement surveillance schedules. Respondents support evidence-based protocols, which bodes well for care standardization. Results will inform the first multi-institutional EA databases in the United States (US), which will be essential for evidence-based care.Level of EvidenceThis is a prognosis study with level 4 evidence. 相似文献
5.
6.
7.
8.
9.
Sirt5 is known to functionally regulate mitochondrial proteins by altering posttranslational modifications, including lysine desuccinylation. While roles for Sirt5 as either a tumor promoter or suppressor, or in chemoresistance, have been implicated in other cancers, the function of Sirt5 in cutaneous melanoma has not been well examined. Therefore, to determine whether Sirt5 is necessary for BrafV600E‐mediated melanoma formation and/or disease progression, we crossed a genetically engineered murine melanoma model (TyrCreERT2/+; BrafLSL‐V600E/+; Ptenflox/flox) to Sirt5?/? knockout animals. In addition, we tested for synergism with a selective BRAF (V600E) inhibitor in Sirt5?/? mouse melanoma cells. Taken together, this report demonstrates that, in these models, Sirt5 is dispensable for BrafV600E‐mediated cutaneous melanoma formation and growth in vivo, and does not improve sensitivity to a selective BRAF inhibitor. 相似文献
10.